Literature DB >> 23977698

New anti-inflammatory targets for chronic obstructive pulmonary disease.

Peter J Barnes1.   

Abstract

Chronic obstructive pulmonary disease (COPD) is associated with chronic inflammation of the peripheral airways and lung parenchyma, which leads to progressive obstruction of the airways. Current management with long-acting bronchodilators does not reduce disease progression, and there are no treatments that effectively suppress chronic inflammation in COPD. An increased understanding of the inflammatory processes that are involved in the pathophysiology of COPD has identified several new therapeutic targets. This Review discusses some of the most promising of these targets, including new antioxidants, kinase inhibitors and drugs that target cellular senescence, microbial colonization, epigenetic regulation of inflammatory gene expression and corticosteroid resistance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23977698     DOI: 10.1038/nrd4025

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  154 in total

Review 1.  Global burden of COPD: risk factors, prevalence, and future trends.

Authors:  David M Mannino; A Sonia Buist
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

2.  The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one].

Authors:  Victoria Boswell-Smith; Domenico Spina; Alec W Oxford; Mike B Comer; Esther A Seeds; Clive P Page
Journal:  J Pharmacol Exp Ther       Date:  2006-05-08       Impact factor: 4.030

Review 3.  The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.

Authors:  Armin Hatzelmann; Esteban J Morcillo; Giuseppe Lungarella; Serge Adnot; Shahin Sanjar; Rolf Beume; Christian Schudt; Hermann Tenor
Journal:  Pulm Pharmacol Ther       Date:  2010-04-07       Impact factor: 3.410

4.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

Authors:  Kim A Papp; Craig Leonardi; Alan Menter; Jean-Paul Ortonne; James G Krueger; Gregory Kricorian; Girish Aras; Juan Li; Chris B Russell; Elizabeth H Z Thompson; Scott Baumgartner
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

5.  Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease.

Authors:  Yasuo To; Kazuhiro Ito; Yasuo Kizawa; Marco Failla; Misako Ito; Tadashi Kusama; W Mark Elliott; James C Hogg; Ian M Adcock; Peter J Barnes
Journal:  Am J Respir Crit Care Med       Date:  2010-03-11       Impact factor: 21.405

6.  Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study.

Authors:  Andrea S Gershon; Laura Warner; Paul Cascagnette; J Charles Victor; Teresa To
Journal:  Lancet       Date:  2011-09-10       Impact factor: 79.321

7.  Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease.

Authors:  Andrew Churg; Caroline V Marshall; Don D Sin; Sarah Bolton; Steven Zhou; Katherine Thain; Elaine B Cadogan; Justine Maltby; Matthew G Soars; Philip R Mallinder; Joanne L Wright
Journal:  Am J Respir Crit Care Med       Date:  2012-01-01       Impact factor: 21.405

8.  Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD.

Authors:  Davinder S Garcha; Sarah J Thurston; Anant R C Patel; Alexander J Mackay; James J P Goldring; Gavin C Donaldson; Timothy D McHugh; Jadwiga A Wedzicha
Journal:  Thorax       Date:  2012-08-03       Impact factor: 9.139

9.  Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.

Authors:  Robert Wilson; Tobias Welte; Eva Polverino; Anthony De Soyza; Hugh Greville; Anne O'Donnell; Jeff Alder; Peter Reimnitz; Barbara Hampel
Journal:  Eur Respir J       Date:  2012-09-27       Impact factor: 16.671

10.  A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice.

Authors:  Marylène Fortin; Hélène D'Anjou; Marie-Eve Higgins; Jasmine Gougeon; Paméla Aubé; Kamel Moktefi; Sonia Mouissi; Serge Séguin; Rosanne Séguin; Paolo M Renzi; Luc Paquet; Nicolay Ferrari
Journal:  Respir Res       Date:  2009-05-20
View more
  118 in total

Review 1.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

2.  HPLC-UV method for simultaneous determination of MK-1775 and AZD-7762 in both acetonitrile-aqueous solution and mouse plasma.

Authors:  Kareem Ebeid; Giang N Ho; Aliasger K Salem
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-12-30       Impact factor: 3.205

3.  Low Vitamin D Status Is Associated with Inflammation in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Lin Fu; Jun Fei; Zhu-Xia Tan; Yuan-Hua Chen; Biao Hu; Hui-Xiang Xiang; Hui Zhao; De-Xiang Xu
Journal:  J Immunol       Date:  2020-12-23       Impact factor: 5.422

Review 4.  Updates in Chronic Obstructive Pulmonary Disease for the Year 2014.

Authors:  Sibel Atış Naycı; Lütfi Çöplü; Alev Gürgün; Nurdan Köktürk; Mehmet Polatlı; Elif Şen; Sema Umut; Esra Uzaslan; Nurhayat Yıldırım; Peter J Barnes
Journal:  Turk Thorac J       Date:  2015-04-01

Review 5.  The matrikine PGP as a potential biomarker in COPD.

Authors:  Mojtaba Abdul Roda; Amanda M Fernstrand; Frank A Redegeld; J Edwin Blalock; Amit Gaggar; Gert Folkerts
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-04-10       Impact factor: 5.464

Review 6.  Chronic kidney disease and premature ageing.

Authors:  Jeroen P Kooman; Peter Kotanko; Annemie M W J Schols; Paul G Shiels; Peter Stenvinkel
Journal:  Nat Rev Nephrol       Date:  2014-10-07       Impact factor: 28.314

7.  Cigarette smoke compounds induce cellular redox imbalance, activate NF-κB, and increase TNF-α/CRP secretion: a possible pathway in the pathogenesis of COPD.

Authors:  Tapan Dey; Prachurjya Dutta; Prasenjit Manna; Jatin Kalita; Hari Prasanna Deka Boruah; Alak Kumar Buragohain; Balagopalan Unni; Dibyajyoti Ozah; Mihir Kumar Goswami; Ratan Kumar Kotokey
Journal:  Toxicol Res (Camb)       Date:  2016-03-03       Impact factor: 3.524

8.  Effects of VLA-1 Blockade on Experimental Inflammation in Mice.

Authors:  Ryuichi Totsuka; Takaaki Kondo; Shigeki Matsubara; Midori Hirai; Yoichi Kurebayashi
Journal:  Kobe J Med Sci       Date:  2016-07-05

9.  Enhancing Virtual Screening Performance of Protein Kinases with Molecular Dynamics Simulations.

Authors:  Tavina L Offutt; Robert V Swift; Rommie E Amaro
Journal:  J Chem Inf Model       Date:  2016-10-03       Impact factor: 4.956

10.  Exome Sequencing Analysis in Severe, Early-Onset Chronic Obstructive Pulmonary Disease.

Authors:  Dandi Qiao; Christoph Lange; Terri H Beaty; James D Crapo; Kathleen C Barnes; Michael Bamshad; Craig P Hersh; Jarrett Morrow; Victor M Pinto-Plata; Nathaniel Marchetti; Raphael Bueno; Bartolome R Celli; Gerald J Criner; Edwin K Silverman; Michael H Cho
Journal:  Am J Respir Crit Care Med       Date:  2016-06-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.